Newsletter | September 16, 2025

09.16.25 -- STREAM Edition: Developing CRISPR-GPT, An AI-Driven Multi-Agent System

SPONSOR

 

 

Discover how allogeneic NK cell therapies are reshaping cancer immunotherapy! Join Cell & Gene's Erin Harris as she hosts industry leaders for a dynamic discussion on their groundbreaking, complementary approaches. Don’t miss this inside look at the future of cell therapy—Register now for free! This event is supported by ThermoFisher Scientific.

Accelerating mAb Process Development In The Growing Therapeutics Market

Webinar | Thermo Fisher Scientific Bioproduction

The market for mAbs and mAb variants is growing rapidly. Explore the latest strategies and advancements in early stage mAb upstream and downstream process development.

 

Early-Phase Whole-Body PK As A Solution

Video | Aliri Bioanalysis

Accelerate your path to the clinic with Aliri’s cost-effective, label-free whole-body PK service — designed to deliver deeper insights, faster decisions, and better outcomes for your drug candidates.

Moving Healthcare Innovation Forward

Video | Charter Medical

Charter Medical designs, develops, and manufactures single-use solutions for cell and gene therapies, rising to meet an industry demands for scalable solutions.

Preparing For FDA Pre-Approval Inspection: Quality And Regulatory Topics

Webinar | Lonza

Consider these strategies for meeting quality and regulatory requirements in cell and gene therapies that can also help to identify issues early, reduce risks, and prevent delays and rework.

Inside CRISPR-GPT With Yuanhao Qu

Video | Cell & Gene

In this Cell & Gene Podcast episode, Host Erin Harris talks to Stanford School of Medicine Ph.D. student, Yuanhao Qu, about his work developing CRISPR-GPT, an AI-driven multi-agent system designed to automate genetic experimental design and data analysis, making CRISPR experiments more efficient and accessible.

Mastering The Complexities Of Gene Therapy Document Writing

Webinar | inSeption Group

Gain the insight and strategic flexibility needed to confidently navigate the unique scientific, regulatory, and documentation challenges of gene therapy development.